Organoid Biobanks & Platform Leaders
Companies with extensive organoid biobanks and validated discovery platforms
HUB Organoids
Adult stem cell-derived organoids. Founded by Hans Clevers (Nature breakthrough). Acquired by Merck December 2024. Largest academic biobank.
Crown Bioscience
Patient-derived tumor organoids for oncology. HuTumorX platform with 2,500+ models. JSR Life Sciences acquisition.
InSphero
Scaffold-free 3D microtissues. Liver and pancreatic islet models. Akura technology platform. 200+ pharma customers.
Champions Oncology
TumorGraft platform for PDX and organoid models. NASDAQ: CSBR. Cancer translational research services.
iPSC-Derived Organoid Leaders
Companies using induced pluripotent stem cells for organoid production
System1 Biosciences
Brain organoids with vascularization. CNS disease modeling. UCSF spinout. Precision psychiatry platform.
Newcells Biotech
iPSC-derived kidney and retinal models. Newcastle University spinout. UK biotech with NHS partnerships.
Novoheart
MyHeart platform for cardiac organoids. Human heart-in-a-jar technology. Hong Kong-based.
Bit Bio
Precision cellular reprogramming. opti-ox technology for consistent iPSC differentiation. Cambridge, UK.
3D Bioprinting & Tissue Engineering
Companies creating complex 3D tissue structures through bioprinting
Organovo
3D bioprinting pioneer. ExVive liver and kidney tissues. Pivoted to therapeutics. OTC listed.
Volumetric
Light-based bioprinting technology. Rapid tissue fabrication. Aspect Biosystems competitor.
Aspect Biosystems
Microfluidic bioprinting for tissues. Type 1 diabetes cell therapy. Johnson & Johnson partnership.
CELLINK (Bico)
Bioprinting hardware and bioinks. Acquired by Bico Group. Global bioprinting ecosystem.
Gut Organoid & Epithelial Specialists
Companies focused on intestinal and barrier tissue models
Altis Biosystems
RepliGut platform for intestinal models. Primary tissue, not cell lines. Duke University spinout.
MatTek Corporation
EpiDerm and EpiAirway tissue models. Gold standard for dermal testing. 35+ years experience.
EpiSkin (L'Oréal)
Reconstructed human skin models. L'Oréal subsidiary. Regulatory-accepted alternatives.
Seed Health
Microbiome research with organoid integration. Gut-brain axis studies. Consumer and pharma focus.
Sector Analysis
Market Overview
- + Organoid market projected to reach $4.5B by 2030 (17% CAGR)
- + Merck acquisition of HUB Organoids (Dec 2024) validates sector
- + Patient-derived tumor organoids becoming standard for oncology
- + Brain organoids advancing neurological disease research
- + Integration with AI and organ-on-chip driving hybrid platforms
Key Applications
Patient-derived tumor organoids for drug sensitivity testing.
Patient-specific models for treatment selection.
Genetic diseases and rare disease research.
Transplantation and tissue replacement therapies.
Explore More Categories
Discover companies across all human-relevant technology sectors